226 related articles for article (PubMed ID: 16369667)
21. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.
Kim NJ; Park SJ; Choi SH; Lee MS; Choo EJ; Kwak YG; Woo JH; Ryu J; Jeong JY; Kim YS
Microb Drug Resist; 2005; 11(3):260-5. PubMed ID: 16201929
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria.
Gómez-Garcés JL; Alos JI; Tamayo J
Int J Antimicrob Agents; 2007 Jun; 29(6):688-92. PubMed ID: 17475450
[TBL] [Abstract][Full Text] [Related]
23. In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens.
Soriano F; Fernández-Roblas R; Calvo R; García-Calvo G; Pardeiro M; Bryskier A
J Antimicrob Chemother; 1998 Nov; 42(5):647-9. PubMed ID: 9848450
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria.
Martínez-Martínez L; Pascual A; Suárez AI; Perea EJ
Antimicrob Agents Chemother; 1998 Dec; 42(12):3290-2. PubMed ID: 9835530
[TBL] [Abstract][Full Text] [Related]
25. Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):494-7. PubMed ID: 11561807
[TBL] [Abstract][Full Text] [Related]
26. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.
Jalava J; Kataja J; Seppälä H; Huovinen P
Antimicrob Agents Chemother; 2001 Mar; 45(3):789-93. PubMed ID: 11181362
[TBL] [Abstract][Full Text] [Related]
29. Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest.
Conejo Mdel C; Martínez-Martínez L; Pascual A; Suárez AI; Perea EJ
Antimicrob Agents Chemother; 2003 Apr; 47(4):1403-6. PubMed ID: 12654678
[TBL] [Abstract][Full Text] [Related]
30. [Susceptibility of Staphylococcus aureus to new macrolide antibiotics].
Sacha P; Wieczorek P; Jakoniuk P
Przegl Lek; 2008; 65(5):225-8. PubMed ID: 18853646
[TBL] [Abstract][Full Text] [Related]
31. The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against gram-positive bacilli and development of resistance.
Fernández-Roblas R; Calvo R; Esteban J; Bryskier A; Soriano F
J Antimicrob Chemother; 1999 Feb; 43(2):285-9. PubMed ID: 11252337
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium.
Verhaegen J; Verbist L
Acta Clin Belg; 2001; 56(6):349-53. PubMed ID: 11881319
[TBL] [Abstract][Full Text] [Related]
33. Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.
Reinert RR; Al-Lahham A
Antimicrob Agents Chemother; 2005 Jul; 49(7):3011-3. PubMed ID: 15980387
[TBL] [Abstract][Full Text] [Related]
34. New Gene Responsible for Resistance of Clinical Corynebacteria to Macrolide, Lincosamide and Streptogramin B.
Szemraj M; Kwaszewska A; Szewczyk EM
Pol J Microbiol; 2018 Jun; 67(2):237-240. PubMed ID: 30015464
[TBL] [Abstract][Full Text] [Related]
35. Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations.
Farrell DJ; Shackcloth J; Barbadora KA; Green MD
Antimicrob Agents Chemother; 2006 Feb; 50(2):817-8. PubMed ID: 16436755
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.
Engler KH; Warner M; George RC
J Antimicrob Chemother; 2001 Jan; 47(1):27-31. PubMed ID: 11152428
[TBL] [Abstract][Full Text] [Related]
37. Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci.
Jacobs MR; Bajaksouzian S; Appelbaum PC
J Antimicrob Chemother; 2003 Nov; 52(5):809-12. PubMed ID: 14519674
[TBL] [Abstract][Full Text] [Related]
38. Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003.
Malhotra-Kumar S; Lammens C; Chapelle S; Wijdooghe M; Piessens J; Van Herck K; Goossens H
Emerg Infect Dis; 2005 Jun; 11(6):939-42. PubMed ID: 15963292
[TBL] [Abstract][Full Text] [Related]
39. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.
Schito GC; Marchese A; Elkharrat D; Farrell DJ;
J Chemother; 2004 Feb; 16(1):13-22. PubMed ID: 15077994
[TBL] [Abstract][Full Text] [Related]
40. Resistance phenotypes conferred by macrolide phosphotransferases.
Chesneau O; Tsvetkova K; Courvalin P
FEMS Microbiol Lett; 2007 Apr; 269(2):317-22. PubMed ID: 17302923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
